NASDAQ · AVBP
Healthcare · Biotechnology
$29.79
Down-$1.09 (-3.66%)
Updated Sep 10, 2026, 8:10 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
AVBP closed at $29.79 after 20 trading sessions, down 5.31% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $30.02 | $30.26 | $29.40 | $29.79 | 280.14K |
| Sep 8, 2026 | $30.57 | $31.40 | $30.02 | $30.28 | 721.96K |
| Sep 4, 2026 | $30.79 | $31.45 | $30.595 | $30.95 | 182.98K |
| Sep 3, 2026 | $30.58 | $31.39 | $30.22 | $31.03 | 465.36K |
| Sep 2, 2026 | $30.33 | $30.79 | $29.60 | $30.51 | 423.87K |
| Sep 1, 2026 | $30.10 | $30.325 | $29.695 | $30.15 | 356.09K |
| Aug 31, 2026 | $29.94 | $30.26 | $29.35 | $30.05 | 369.58K |
| Aug 28, 2026 | $30.53 | $31.37 | $29.75 | $30.17 | 353.46K |
| Aug 27, 2026 | $30.79 | $31.765 | $30.24 | $31.00 | 299.97K |
| Aug 26, 2026 | $31.21 | $31.41 | $30.11 | $31.14 | 433.84K |
| Aug 25, 2026 | $28.64 | $31.52 | $28.64 | $31.35 | 961.65K |
| Aug 24, 2026 | $29.02 | $29.02 | $28.05 | $28.26 | 225.59K |
| Aug 21, 2026 | $29.45 | $29.77 | $28.95 | $29.12 | 304.81K |
| Aug 20, 2026 | $29.73 | $29.81 | $28.64 | $29.18 | 406.27K |
| Aug 19, 2026 | $30.13 | $30.45 | $29.31 | $30.02 | 522.88K |
| Aug 18, 2026 | $28.86 | $30.365 | $28.86 | $30.00 | 408.73K |
| Aug 17, 2026 | $29.30 | $29.634 | $28.57 | $29.01 | 455.16K |
| Aug 14, 2026 | $29.99 | $30.07 | $29.13 | $29.51 | 439K |
| Aug 13, 2026 | $30.73 | $30.96 | $29.40 | $30.00 | 478.87K |
| Aug 12, 2026 | $31.18 | $31.60 | $30.86 | $31.46 | 295.75K |
The latest Smart Investors Daily articles mentioning AVBP.
AVBP research
Company profile and research snapshot.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 13, 2026 | Citigroup | Buy | — |
| Aug 13, 2026 | Guggenheim | Buy | — |
| Aug 13, 2026 | BTIG | Buy | — |
| May 29, 2026 | Truist Securities | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Aug 27, 2026
ArriVent BioPharma is also advancing ARR-002, a novel dual-target therapy for patients with ovarian and endometrial cancers. Read more on AVBP stock here.
Benzinga · Aug 17, 2026
HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $44 to $47.
Benzinga · Aug 13, 2026
Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $43 to $40.
Benzinga · Aug 13, 2026
Guggenheim analyst Michael Schmitz reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $45 price target.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AVBP.
